These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7665720)

  • 1. The effect of lovastatin on early restenosis.
    Beigel Y; Zafrir N; Teplitzky Y; Neuman Y; Gavish D; Wurzel M; Fainaru M
    J Clin Pharmacol; 1995 Jun; 35(6):599-605. PubMed ID: 7665720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Background and methods for the lovastatin restenosis trial after percutaneous transluminal coronary angioplasty. The Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Brown CL; Cohen CL; Hirsch LJ; King SB; Alexander RW
    Am J Cardiol; 1992 Aug; 70(3):293-9. PubMed ID: 1632391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of restenosis by lovastatin after successful coronary angioplasty.
    Sahni R; Maniet AR; Voci G; Banka VS
    Am Heart J; 1991 Jun; 121(6 Pt 1):1600-8. PubMed ID: 2035374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin E supplementation, plasma lipids and incidence of restenosis after percutaneous transluminal coronary angioplasty (PTCA).
    DeMaio SJ; King SB; Lembo NJ; Roubin GS; Hearn JA; Bhagavan HN; Sgoutas DS
    J Am Coll Nutr; 1992 Feb; 11(1):68-73. PubMed ID: 1541798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT).
    Kleemann A; Eckert S; von Eckardstein A; Lepper W; Schernikau U; Gleichmann U; Hanrath P; Fleck E; Neiss A; Kerber S; Assmann G; Breithardt G;
    Eur Heart J; 1999 Oct; 20(19):1393-406. PubMed ID: 10487800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of restenosis after coronary balloon angioplasty: rationale and design of the Fluvastatin Angioplasty Restenosis (FLARE) Trial. The FLARE Study Group.
    Foley DP; Bonnier H; Jackson G; Macaya C; Shepherd J; Vrolix M; Serruys PW
    Am J Cardiol; 1994 May; 73(14):50D-61D. PubMed ID: 8198025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lack of effect of lovastatin on restenosis after coronary angioplasty. Lovastatin Restenosis Trial Study Group.
    Weintraub WS; Boccuzzi SJ; Klein JL; Kosinski AS; King SB; Ivanhoe R; Cedarholm JC; Stillabower ME; Talley JD; DeMaio SJ
    N Engl J Med; 1994 Nov; 331(20):1331-7. PubMed ID: 7935702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation.
    Karsch KR; Preisack MB; Baildon R; Eschenfelder V; Foley D; Garcia EJ; Kaltenbach M; Meisner C; Selbmann HK; Serruys PW; Shiu MF; Sujatta M; Bonan R
    J Am Coll Cardiol; 1996 Nov; 28(6):1437-43. PubMed ID: 8917255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty.
    Watanabe K; Sekiya M; Ikeda S; Miyagawa M; Hashida K
    Am Heart J; 1996 Jul; 132(1 Pt 1):23-9. PubMed ID: 8701872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial.
    Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R
    Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial.
    Serruys PW; Foley DP; Jackson G; Bonnier H; Macaya C; Vrolix M; Branzi A; Shepherd J; Suryapranata H; de Feyter PJ; Melkert R; van Es GA; Pfister PJ
    Eur Heart J; 1999 Jan; 20(1):58-69. PubMed ID: 10075142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of an acute reduction in lipoprotein(a) with coronary artery restenosis after percutaneous transluminal coronary angioplasty.
    Horie H; Takahashi M; Izumi M; Takaoka A; Fujita T; Sakamoto T; Kito O; Okamura H; Kinoshita M
    Circulation; 1997 Jul; 96(1):166-73. PubMed ID: 9236431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of restenosis after coronary angioplasty with low-density lipoprotein apheresis.
    Adachi H; Niwa A; Shinoda T
    Artif Organs; 1995 Dec; 19(12):1243-7. PubMed ID: 8967882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
    Circulation; 1992 Jul; 86(1):100-10. PubMed ID: 1535568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Short-term and long-term effects of low-density lipoprotein (LDL) apheresis on restenosis after percutaneous transluminal coronary angioplasty (PTCA): is lowering Lp(a) by LDL apheresis effective on restenosis after PTCA?
    Kanemitsu S; Takekoshi N; Matsui S; Tsugawa H; Ohkubo S; Kitayama M; Matsuda T; Senma J; Masuyama K; Yamagata T; Murakami E
    Ther Apher; 1998 Feb; 2(1):65-70. PubMed ID: 10227791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggressive lipid lowering in postcoronary angioplasty patients with elevated cholesterol (the Lovastatin Restenosis Trial).
    Boccuzzi SJ; Weintraub WS; Kosinski AS; Roehm JB; Klein JL
    Am J Cardiol; 1998 Mar; 81(5):632-6. PubMed ID: 9514463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of coronary restenosis by exercise electrocardiography thallium-201 perfusion imaging and coronary angiography in asymptomatic patients after percutaneous transluminal coronary angioplasty.
    Beygui F; Le Feuvre C; Maunoury C; Helft G; Antonietti T; Metzger JP; Vacheron A
    Am J Cardiol; 2000 Jul; 86(1):35-40. PubMed ID: 10867089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Restenosis and clinical outcome in patients treated with amlodipine after angioplasty: results from the Coronary AngioPlasty Amlodipine REStenosis Study (CAPARES).
    Jørgensen B; Simonsen S; Endresen K; Forfang K; Vatne K; Hansen J; Webb J; Buller C; Goulet G; Erikssen J; Thaulow E
    J Am Coll Cardiol; 2000 Mar; 35(3):592-9. PubMed ID: 10716459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial.
    Serruys PW; Klein W; Tijssen JP; Rutsch W; Heyndrickx GR; Emanuelsson H; Ball SG; Decoster O; Schroeder E; Liberman H
    Circulation; 1993 Oct; 88(4 Pt 1):1588-601. PubMed ID: 8403306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty.
    Tsuchikane E; Fukuhara A; Kobayashi T; Kirino M; Yamasaki K; Kobayashi T; Izumi M; Otsuji S; Tateyama H; Sakurai M; Awata N
    Circulation; 1999 Jul; 100(1):21-6. PubMed ID: 10393676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.